FDA Explains Why It Approved Apple Watch's De Novo Despite Missing Primary Endpoint

 
• By Ferdous Al-Faruque
Apple Watch
FDA has shed more light on its de novo approvals of cardiac apps on the Apple Watch

More from Approvals

More from Policy & Regulation